ENDONOVO THERAPEUTICS, INC. (ENDV)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 150K 300K 450K FY10: 51.2K FY11: 45.5K FY12: 30.6K FY13: 22.9K FY14: 24.2K FY15: 4.3K FY18: 83.3K FY19: 310.2K FY20: 165.8K FY21: 73.1K FY22: 135.4K FY10 FY11 FY12 FY13 FY14 FY15 FY18 FY19 FY20 FY21 FY22

Gross Profit Annual

0 80K 160K 240K FY13: 8.9K FY14: 8.7K FY15: 2.1K FY18: 70.3K FY19: 216.8K FY20: 100.4K FY21: 58.1K FY22: 125.4K FY13 FY14 FY15 FY18 FY19 FY20 FY21 FY22

Operating Income Annual

-6M -4M -2M 0 2M 4M 6M FY10: -78K FY11: -95.5K FY12: -1.7M FY13: -2.4M FY14: -2.2M FY15: -2.6M FY16: -5.4M FY17: -4.6M FY18: -4.2M FY19: -3.8M FY20: -2.9M FY21: -2.2M FY22: -3.3M FY10 FY12 FY14 FY16 FY18 FY20 FY22

Net Income Annual

-21M -14M -7M 0 7M 14M 21M FY10: -69.4K FY11: -94.1K FY12: -1.9M FY13: -2.9M FY14: -959.5K FY15: -6.8M FY16: -5.3M FY17: -10.8M FY18: -6.4M FY19: -17.3M FY20: -395.6K FY21: -3.1M FY22: -18.5M FY10 FY12 FY14 FY16 FY18 FY20 FY22

Cost of Revenue Annual

0 35K 70K 105K FY18: 12.9K FY19: 93.4K FY20: 65.4K FY21: 15K FY22: 10K FY18 FY19 FY20 FY21 FY22

Operating Cash Flow Annual

-3M -1.5M 0 1.5M 3M 4.5M FY10: 8.5K FY11: -50.4K FY12: -284.9K FY13: -257.4K FY14: -909.3K FY15: -1M FY16: -2.5M FY17: -3M FY18: -2.9M FY19: -2.5M FY20: -741.6K FY21: -986.6K FY22: -678.8K FY10 FY12 FY14 FY16 FY18 FY20 FY22

Free Cash Flow Annual

-3M -2M -1M 0 1M 2M 3M FY14: -909.3K FY15: -1M FY18: -2.9M FY19: -2.5M FY14 FY15 FY18 FY19

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 50M 100M 150M FY10: 4.5M FY11: 4.5M FY12: 48.1M FY21: 59.8M FY22: 139.2M FY10 FY11 FY12 FY21 FY22

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q4 '12: -0.04 Q1 '13: -0.05 Q2 '13: -0.05 Q3 '13: -0.05 Q4 '13: -3.97 Q1 '14: -3.96 Q2 '14: -3.69 Q3 '14: -3.68 Q4 '15: -0.08 Q1 '16: -0.08 Q2 '16: -0.08 Q3 '16: -0.09 Q4 '16: -0.05 Q1 '17: -0.09 Q2 '17: -0.07 Q3 '17: -0.08 Q4 '17: -0.04 Q1 '18: 0.01 Q2 '18: 0.00 Q3 '18: 0.01 Q4 '18: -17.76 Q1 '19: -22.75 Q2 '19: -36.32 Q3 '19: -38.11 Q4 '19: -45.18 Q1 '20: -40.33 Q2 '20: -26.93 Q3 '20: -25.19 Q4 '20: -0.03 Q1 '21: 0.05 Q2 '21: 0.20 Q3 '21: 0.25 Q4 '21: -0.05 Q1 '22: -0.02 Q2 '22: -0.02 Q3 '22: 0.00 Q4 '22: -0.13 Q1 '23: -0.10 Q2 '13 Q3 '14 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.